Serum to urinary prostate specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

This study was designed to evaluate the serum to urinary PSA ratio as new parameter for early detection of prostate cancer in addition to serum PSA. The study included 40 patients; 30 patients with BPH, 10 patients with prostate carcinoma and 10 control subjects. Serum PSA was measured by VIDAS whereas urinary PSA was measured by a double antibody radioimmunoassay and serum-to-urinary PSA ratio was calculated. It was sfound that serum-to-urinary PSA ratio can discrimininate between prostate cancer and BPH in event of a lack of significant difference between the serum PSA levels. We suggest that the concept of serum-to-urinary PSA ratio offer a new parameter for early detection of prostate cancer in addition to total serum PSA